Alerta

PREVENTION AND/OR TREATMENT OF CARDIAC DAMAGE

Resumen de: WO2023247047A1

The present invention refers to a peptide, comprising or consisting of SEQ ID NO: 1 (CAYMTMKIRN), for use as a medicament, preferably in the prevention and/or treatment of cardiac damage arising after ischemia followed by reperfusion, or in the prevention and/or treatment of the inflammatory response following acute myocardial infarction. In a preferred embodiment, the peptide is conjugated with a nanoparticle.

LIPID STRUCTURES AND COMPOSITIONS COMPRISING SAME

Resumen de: AU2023288487A1

The disclosure relates to ionizable lipids and compositions comprising the ionizable lipids. Lipid-nanoparticle compositions comprised of an ionizable lipid, optionally in combination with other lipid components such as helper lipids, stabilization lipids and structural lipids, and a therapeutic agent, such as a nucleic acid, for delivery to mammalian cells or organs are described.

CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA

Resumen de: AU2023288520A1

Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes an antigen. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.

COMBINATION THERAPIES

Resumen de: AU2022463987A1

The present invention relates to combination therapies for treating cancer, optionally chemotherapy-resistant cancers, in a subject. The combination therapies comprise (a) an antibody or antigen-binding portion thereof that specifically binds to CD40, and (b) chemotherapy. The invention also relates to pharmaceutical compositions, kits and methods of using such therapies.

NANOBODY AND NANOBODY-DRUG CONJUGATE TARGETING CD73, METHOD FOR PREPARING SAME, AND USE THEREOF

Resumen de: EP4545561A1

The present invention relates to a novel nanobody (Nb) and a nanobody-drug conjugate (NDC) targeting CD73, a method for preparing same, and use thereof. The monoclonal nanobody and the corresponding NDC can efficiently bind to isolated CD73, various tumor cells and CD73 on the surface of an immune cell with high specificity and block the catalytic activity of CD73 enzymes, exhibiting high affinity, low immunogenicity, and a significant anti-tumor effect.

RAPIDLY DISSOLVING AND ORODISPERSIBLE NANOFIBERS LOADED WITH RISPERIDONE PRODUCED BY ELECTROSPINNING METHOD

一种液态金属纳米颗粒光热材料的制备方法

Resumen de: CN119896731A

本发明属于光热材料制备技术领域，具体涉及一种液态金属纳米颗粒光热材料的制备方法，包括：步骤1、配制海藻酸钠水溶液；步骤2、在海藻酸钠水溶液中加入镓基液态金属，先通过搅拌混合，再通过超声处理充分混合；步骤3、干燥后得到生成物。本发明的制备过程是在常规环境下制备，对环境的要求低。另外，本发明制备的纳米颗粒具有稳定性好、光热性能佳、制备方法简单、形成速率快、易控制的特点，可制备具有高效光热能力的材料。综合以上有益效果，本发明在光热材料制备技术领域具有良好的应用前景。

一种基于脐带间充质干细胞囊泡负载I型光敏前药的纳米囊泡及其制备方法与应用

Resumen de: CN119899206A

本发明公开了一种基于脐带间充质干细胞囊泡负载I型光敏前药的纳米囊泡及其制备方法与应用，其包括来源于人脐间充质干细胞的囊泡及其负载的所述I型光敏前药。本发明的优点包括：纳米囊泡EVs@NBS‑PB的I型光敏前药可与糖尿病慢性伤口微环境中高水平的H2O2响应释放I型光敏剂，再通过激光激发后产生PDT效应释放活性氧达到抗菌的目的，实现对糖尿病慢性创面的靶向抗感染作用，结合来源于人脐间充质干细胞的囊泡调节伤口微环境来协同治疗慢性创面；干细胞囊泡不仅能够提高光敏前药的生物相容性，同时还具有促细胞增殖、迁移及血管生成的作用；用水凝胶微针贴片装载给药的方式不仅具有高药物递送效率和微创性，同时也能提高患者的依从性。

一种基于磷酸钙介导的外泌体药物递送系统及制备方法

Resumen de: CN119896651A

本发明属于生物技术技术领域，具体涉及一种基于磷酸钙介导的外泌体药物递送系统，并进一步公开其制备方法与应用。本发明所述基于磷酸钙介导的外泌体药物递送系统，通过Ca2+和磷酸盐构建形成磷酸钙介导的外泌体递送体系，通过氯化钙转染miRNA后可以将核酸药物载入到外泌体中，外泌体中miRNA的含量显著提高，进而借助于外泌体的递送性能将药物运输，有效提高了药物的载药效率和递送效率，具有装载效率高的优势。

用于光热疗法的自组装纳米粒子

Resumen de: CN119899218A

本文描述了作为光热转导剂的环金属化铁(II)络合物。所公开的络合物表现出高结构稳健性和在近红外(NIR)和可见光区域的显著吸收。所描述的络合物可以自组装以形成金属超分子粒子，其具有优异的光热性能并可以通过EPR效应靶向肿瘤。例如，本文公开的Fe NP具有强的近红外(NIR)吸光度，在近红外(例如，808nm)激光照射下具有至少30％(例如约60％)的高光热转换效率和/或优异的光热稳定性。Fe NP可以用包衣剂(例如牛血清白蛋白)包衣以形成包衣的Fe NP，这可以进一步增强金属超分子粒子在体内的肿瘤积累和生物相容性。Fe NP的优异光热性能使其能够解决与大多数现有光热材料相关的光热转换效率低的问题。

一种高效表达GBA1的mRNA及其应用

Resumen de: CN119899835A

本申请公开了一种高效表达GBA1的mRNA及其应用。本申请高效表达GBA1的mRNA由5’端至3’端依序包括5’甲基化帽子、5’UTR、目的基因序列、3’UTR和polyA尾巴；其中，目的基因序列为编码GBA1蛋白或GBA1突变蛋白的序列。本申请高效表达GBA1的mRNA，通过修改mRNA不同元件来获得更稳定、表达效率更高的GBA1mRNA。

一种用于抑制新生血管生成的自组装多肽及其制备方法和应用

Resumen de: CN119874811A

本发明涉及一种用于抑制新生血管生成的自组装多肽及其制备方法和应用，所述自组装多肽包括疏水单元、组装单元、特异性靶向Tie2受体的多肽和特异性靶向VEGFR2受体的多肽。本发明提供的自组装多肽同时靶向Tie2受体和VEGFR2受体，特异性靶向血管内皮细胞，在亲疏水作用下自组装形成纳米颗粒，经过配受体相互作用后，由纳米颗粒转变为纳米纤维，阻碍VEGF结合VEGFR2和Ang2结合Tie2，实现在新生血管病灶区域的快速富集，抑制内皮细胞迁移，进而抑制血管的生成。

一种雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料及其应用

Resumen de: CN119868303A

本申请公开了一种雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料及其应用，属于纳米材料合成领域。该雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料为纳米级颗粒，呈方块状结构，包括方块状普鲁士蓝纳米颗粒和包覆在普鲁士蓝纳米颗粒外的雷公藤外泌体样纳米囊泡。通过将雷公藤外泌体纳米囊泡PELNVs加入到普鲁士蓝纳米颗粒溶液中混合，将混合后的体系采用物理挤压使其反复通过聚碳酸酯膜制备得到。所得雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料具备优异的光热转换性能和抗氧化性能，且溶血率保持极低水平，细胞毒性低，用于类风湿关节炎光热治疗，具有优异的光热治疗能力，生物安全性好，应用前景广泛。

一种白蛋白维替泊芬纳米粒的制备方法及其应用

Resumen de: CN119868544A

本发明涉及生物医药技术领域，尤其涉及一种白蛋白维替泊芬纳米粒的制备方法及其应用。白蛋白维替泊芬纳米粒在治疗肿瘤中的应用；白蛋白维替泊芬纳米粒的制备方法，步骤如下：将白蛋白聚合物水溶液与维替泊芬高速搅拌反应，并通过100kDa超滤管纯化。本发明提供的一种白蛋白维替泊芬纳米粒的制备方法及其应用，制得的白蛋白维替泊芬纳米粒，其仅能明显增加穿过细胞的药物量，进入细胞后维替泊芬的光动力效应还具有抗肿瘤效果。

T细胞的活化/增殖方法

Resumen de: MX2021004357A

The present invention provides: a method which is for the activation and/or proliferation of T cells and includes a step for bringing a T cell-containing cell population into contact with a nucleic acid delivery carrier having a surface to which at least one T cell-activating ligand is added; a method which is for delivering a nucleic acid into a T cell and includes a step for bringing a T cell-containing cell population into contact with (a) a nucleic acid delivery carrier that has a surface to which at least one T cell-activating ligand is added and that contains a nucleic acid therein, or (b) both of at least one T cell-activating ligand and a nucleic acid delivery carrier that has a surface to which a T cell-activating ligand is not added and that contains a nucleic acid therein; and a method for producing a medicament that contains T cells.

用于核酸递送的2-氨基丙烷-1,3-二醇封端的阳离子类肽

Resumen de: AU2023337954A1

The present disclosure provides delivery vehicle compositions comprising hydroxyalkyl-capped cationic peptoids, such as 2-aminopropane-1,3-diol-capped cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.

用于核酸治疗的脂质纳米颗粒(LNP)组合物或制剂

Resumen de: WO2024044178A1

The present disclosure relates generally to lipid nanoparticle compositions comprising a nucleic acid, an ionizable polymer, a cationic lipid, a phospholipid, a sterol, and a PEG-lipid. Further, the present disclosure relates generally to methods of treating or preventing a disease, comprising administering to a subject in need thereof a lipid nanoparticle composition described herein.

脂质化合物和脂质纳米颗粒组合物

Resumen de: TW202434543A

The present application discloses a compound with a structural formula as shown in formula (I), and a salt or an isomer thereof. The present application also discloses a nanoparticle composition containing the compound and a salt or an isomer thereof. The nanoparticle composition of the present application can efficiently deliver drugs into cells and exert therapeutic or prophylactic effects of drugs.

一种同时递送光敏剂和靶向抗体的纳米颗粒及其制备方法和应用

Resumen de: CN119868309A

一种同时递送光敏剂和靶向抗体的纳米颗粒及其制备方法和应用。本发明提供的纳米颗粒，含有光敏剂、一氧化氮前体、siRNA、和巨噬细胞膜，所述光敏剂为焦脱美叶绿素a分子，所述siRNA为siPD‑L1，所述一氧化氮前体为九聚精氨酸。本发明提供的靶向纳米颗粒可实现光敏剂和siRNA的高效递送。本发明将精氨酸与焦脱镁叶绿酸a按1:1共价连接，制备纳米粒后，通过静电吸附原理负载带负电的siPD‑L1，通过包裹M1巨噬细胞膜囊泡，降低纳米颗粒表面电荷同时提高纳米颗粒的肿瘤靶向能力。在650nm激光照射下可实现光动力和抗PD‑L1免疫联合治疗恶性肿瘤。

脂质化合物和脂质纳米颗粒组合物

Resumen de: TW202440536A

The present application discloses compounds of formula (I), as well as salts and stereoisomers thereof, wherein the variables are as defined in the specification. The present application also discloses nanoparticle compositions comprising the compounds or salts or stereoisomers thereof, and the use of the nanoparticle compositions for delivering active agents.

一种负载过氧化铜的自佐剂化纳米药物及制备方法与应用

Resumen de: CN119868306A

本发明公开了一种负载过氧化铜的自佐剂化纳米药物及制备方法与应用，制备方法包括：制备酰肼化透明质酸；将酰肼化透明质酸经配位和静电吸附作用修饰于纳米氮化铝表面，得到透明质酸化纳米氮化铝；将透明质酸化纳米氮化铝通过铜‑酰肼配位/矿化反应原位制备负载过氧化铜的自佐剂化纳米药物。该纳米药物能响应肿瘤微环境发生分解，进而消耗谷胱甘肽、自供过氧化氢、自生成纳米佐剂、中和肿瘤酸性，可经氨毒性和类芬顿催化活性实现抗肿瘤治疗应用。

一种两亲性氮杂氟硼荧类荧光染料及其制备方法和应用

Resumen de: CN119874737A

本发明公开了一种两亲性氮杂氟硼荧类荧光染料及其制备方法和应用；通过在氮杂氟硼荧类荧光结构中引入两个四甘醇作为亲水结构，引入四个C8或者C18的烷基链作为疏水基元，通过慢加水或者闪沉方式可以组装得到纳米粒子，纳米片以及支化纳米棒结构，并且这些纳米结构在808nm处有非常强的吸收，具有优异的光热转换效果，可以用于肿瘤的光热治疗。

一种重组脂质纳米粒及其制备方法和应用

Resumen de: CN119868308A

本发明属于生物医药技术领域，公开了一种治疗缺血性脑卒中的重组脂质纳米粒及其制备方法和应用。本发明以芹菜籽(Celery seeds，CS)为原材料采用有机溶剂提取法提取脂质，再通过乙醇注入法成功制备芹菜籽重组脂质纳米粒(CS‑rLNPs)。本发明公开的提取工艺简单，原料易得，制备的纳米药物CS‑rLNPs具有生物安全性、稳定性好等优点；经体内外实验表明，CS‑rLNPs能有效穿透血脑屏障和优先分布到缺血半暗区，并能够与脑缺血区域的神经元结合，表现出独特的神经元靶向性；除此之外，该纳米粒对缺血性脑卒中的治疗具有实用价值。因此，本发明的重组脂质纳米粒具有良好的临床应用价值和前景。

一种近红外二区AIE探针与光激活治疗膀胱癌的纳米材料

Resumen de: CN119874723A

本发明提出了一种近红外二区AIE探针与光激活治疗膀胱癌的纳米材料，属于材料化学技术领域，针对光热疗法对膀胱癌治疗效果不佳的问题，本发明设计了一种能够在近红外二区进行高效光热转化的AIE探针，并在其基础上将AIE探针与热敏NO供体共混，将近红外光诱导光热转换释放NO；用两亲性聚合物封装后再修饰细胞膜表面PMCA钙离子通道阻断肽和肿瘤表面FGFR1受体靶向肽，细胞膜表面PMCA钙离子通道阻断肽与热敏NO供体释放的NO共同作用，通过内源性与外源性联合调节钙离子通路，造成肿瘤钙超载，诱导肿瘤细胞凋亡；表面修饰的肿瘤表面FGFR1受体靶向肽可实现该纳米材料在肿瘤部位高效富集，提高治疗效果。本发明所提供的材料为膀胱癌治疗提供了新的思路。

用于持续释放抗体的单体式可植入器件

Nº publicación: CN119894499A 25/04/2025

Solicitante:

塞拉尼斯伊娃高性能聚合物公司

Resumen de: WO2023244526A1

A monolithic implantable device for delivery of an antibody is provided. The implantable device comprises a polymer matrix within which is dispersed a pharmaceutical formulation that includes one or more therapeutic agents and optionally, one or more excipients. The therapeutic agents contain an antibody and the polymer matrix contains a hydrophobic polymer. Within a time period of 35 days, the device exhibits a cumulative weight-based release ratio of the antibody of from about 20% to about 60%.